Author:
Zuo Wei,Liu Bo,Chen Miao,Zhang Bo,Han Bing
Funder
National Natural Science Foundation of China Grants
Fundamental Research Funds for the Central Universities
Chinese Academy of Medical Sciences (CAMS) innovation fund for medical sciences
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference46 articles.
1. US FDA (2014) Promacta (eltrombopag) tablets: US prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022291s012lbl.pdf. Accessed 12 Dec 2021
2. Zhu XF, He HL, Wang SQ, Tang JY, Han B, Zhang DH et al (2019) Current treatment patterns of aplastic anemia in China: a prospective cohort registry study. Acta Haematol 142(3):162–170
3. Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B et al (2012) (2012) Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J of Med 367:11–19
4. Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M et al (2014) Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 123:1818–1825
5. Zuo W, Zhang B, Ruan J, Chen M, Han B (2020) Correlation of the plasma concentration of eltrombopag with efficacy in the treatment of refractory aplastic anemia: a single-centre study in China. Front Pharmacol 11:582625
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献